The sales target for the fiscal year ending December 2028 is 188 billion yen (CAGR +4.3%), operating income 22 billion yen (CAGR +13.8%), and ROE 10%, aiming for 30 consecutive years of dividend increases.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4967","jir_company_name":"Kobayashi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4967-20260210-02.pdf","jir_short_summary":"The sales target for the fiscal year ending December 2028 is 188 billion yen (CAGR +4.3%), operating income 22 billion yen (CAGR +13.8%), and ROE 10%, aiming for 30 consecutive years of dividend increases.","jir_summary":"### Background and Theme of the Medium-Term Management Plan\nKobayashi Pharmaceutical Co., Ltd. has formulated a new medium-term management plan covering the three years from the fiscal year ending December 2026 to the fiscal year ending December 2028. Considering past quality issues related to red yeast rice products, the company aims to balance corporate trust recovery with sustainable growth. The theme is \u201cAchieving Sustainable Growth for the Future\u2014Building Foundations that Connect to Tomorrow,\u201d with five strategic pillars: rebuilding trust, corporate transformation, growth of domestic business, acceleration of global expansion, and capital efficiency management.\n\n### Overview of Performance Targets and Strategies\nThe numerical targets for the fiscal year ending December 2028 are net sales of 188 billion yen (CAGR +4.3%), operating income of 22 billion yen (CAGR +13.8%), EBITDA of 31.5 billion yen (CAGR +10.1%), and ROE of 10%. The dividend policy aims for 30 consecutive years of dividend increases. Market conditions include impacts from the red yeast rice incident, raw material price hikes, and intensified competition. The company plans to prioritize upfront investments and quality-related expenses while targeting profit generation from the second year onward. Resource allocation focuses on quality, capital expenditures, and human resources investment to achieve sustainable growth and enhance corporate value.","jir_financial_highlights":"Net Sales: 188 billion yen (CAGR +4.3%)\nOperating Income: 22 billion yen (CAGR +13.8%)\nEBITDA: 31.5 billion yen (CAGR +10.1%)\nROE: 10% (Unknown (Targeted improvement from 1.7% actual in 2025))\nDividend: 30 consecutive years of dividend increases (Unknown)\nDomestic Net Sales: 131.5 billion yen (CAGR +3.7%)\nInternational Net Sales: 56 billion yen (CAGR +6.0%)","jir_category":"","jir_hashtags":"#KobayashiPharmaceutical, #MediumTermManagementPlan, #BusinessStrategy, #JapaneseStocks","jir_key_figures":"Net Sales Target: 188 billion yen (Fiscal year ending December 2028, CAGR +4.3%)\nOperating Income Target: 22 billion yen (Fiscal year ending December 2028, CAGR +13.8%)\nDividend: Planning 30 consecutive years of dividend increases","jir_meta_title":"Kobayashi Pharmaceutical Announces Medium-Term Management Plan with Sales Target of 188 Billion Yen and Operating Income of 22 Billion Yen","jir_meta_description":"Kobayashi Pharmaceutical has formulated a medium-term management plan for 2026-2028, targeting 188 billion yen in sales, 22 billion yen in operating income, and 10% ROE, with plans for 30 consecutive years of dividend increases. Committed to trust recovery and sustainable growth.","jir_og_title":"Kobayashi Pharmaceutical Announces Medium-Term Management Plan with 188 Billion Yen Sales Target","jir_og_description":"The new medium-term management plan for 2026-2028 aims for 188 billion yen in sales and 22 billion yen in operating income, focusing on sustainable growth and trust recovery.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":7982,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-27078","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n